Skip to main content

Table 1 (abstract O17). Monthly migraine headache days, average of months 1-6

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

 

LFEM

HFEM

 

Treatment

Baseline meana (SD)

N

LSM change from baseline ± SE

LSM change difference ± SE

p-valueb

Baseline meana (SD)

N

LSM change from baseline ± SE

LSM change difference ± SE

p-valueb

p-valuec

Placebo

5.8 (1.1)

295

-0.9 ± 0.2

  

10.9 (2.0)

580

-3.4 ± 0.2

   

Galca 120mg

5.8 (1.1)

150

-2.8 ± 0.3

-1.8 ± 0.3

<.001

10.9 (2.0)

286

-5.4 ± 0.3

-2.0 ± 0.3

<.001

.642

Galca 240mg

5.8 (1.2)

145

-2.3 ± 0.3

-1.4 ± 0.3

<.001

10.7 (2.0)

283

-5.5 ± 0.3

-2.1 ± 0.3

<.001

.101

  1. Galca galcanezumab, N number of subjects who have a non-missing baseline value and at least one post-baseline value;
  2. aBased upon subjects with a non-missing baseline value; bp-value vs. placebo; cTreatment-by-subgroup interaction p-value vs. placebo
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us